This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Cramer's Action Alerts PLUS - See his portfolio and get alerts BEFORE every trade. Learn more NOW!

National Funding Agency For Science And Technology In Portugal Selects Elsevier's Analytical Services To Support Evaluation Of R&D Units

AMSTERDAM, June 10, 2014 /PRNewswire/ --

Data from Scopus ensures up-to-date presentation of researcher IDs in ORCID for five-year review of Portuguese R&D units 

Elsevier, a world-leading provider of scientific, technical and medical information products and services, has announced that it has been selected by the national funding agency for science and technology in Portugal, Fundação para a Ciência e a Tecnologia (FCT), to provide bibliometric analyses that will support its 2013/14 national review assessment of R&D units.

For the first time, FCT's review of R&D units in Portugal will include bibliometric analyses based on data from Elsevier's Scopus, the largest abstract and citation database of peer-reviewed literature. The analyses, which cover research production, impact and collaboration for the 2008-2012 period, are provided by Elsevier's Analytical Services, part of the Elsevier Research Intelligence portfolio of tools.

By selecting Scopus as the data source for the assessment, FCT was able to cover the broadest range of researchers based in Portugal and their publication and citation counts from 2008 to 2012. The 2013/14 assessment exercise includes 324 R&D Units and more than 15,000 researchers.

For the custom bibliometric analyses FCT opted for a process whereby all 15,000 researchers were able to update their unique identifier profiles in ORCID, an open, community-driven effort to create and maintain a registry of unique researcher identifiers and a transparent method of linking research activities and output to these identifiers. Thanks to the free Scopus-to-ORCID feedback wizard, created by Elsevier, researchers in Portugal were able to populate and update their ORCID IDs, ensuring that the bibliometric analyses provided to FCT for the assessment of the R&D units are based on current, accurate data.

Miguel Seabra, FCT President, said, "The bibliometric analyses conducted by Elsevier are an important component of the review process, providing very useful insights for the international review panels. Their involvement will thus contribute to the overall aim of this assessment exercise, which is to reinforce the role of research units as a fundamental pillar in building a modern and competitive scientific system."

Laure Haak, Executive Director of ORCID, said, "Researchers were able to use open tools in ORCID to search for their works, link to their ORCID record and at the same time make any needed adjustments to their Scopus author record. This large-scale implementation of ORCID demonstrated system resilience and scalability, and offers clear hope for researchers requesting to enter research information once, and re-use many times across research systems."

"We are delighted to support FCT with their research evaluation activities, not only by providing them with custom bibliometric analyses, but also in our collaborative approach of updating researcher records in ORCID - a step in the process which benefits all parties involved," said M'hamed el Aisati, Director of Content and Analytics at Elsevier. "We look forward to continue working with FCT, providing data and support for their future assessment initiatives."

1 of 2

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG

Markets

DOW 18,288.63 +155.93 0.86%
S&P 500 2,117.39 +12.89 0.61%
NASDAQ 5,008.0960 +44.5690 0.90%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs